GSK Target Started at GBP19.75 by RBCDow Jones · 9 Sep 2026
Hutchmed (00013.HK) announced that it has entered into a licensing agreement with GlaxoSmithKline for a KRAS-EGFR antibody-drug conjugate cancer therapy.Gelonghui Finance · 3 Sep 2026
US Stock Market Movements | HUTCHMED (HCM.US) Surges Over 14% on Licensing Agreement with GlaxoSmithKline for Cancer DrugZhitong Finance · 3 Sep 2026
GlaxoSmithKline (GSK.US) strengthens its oncology pipeline! Acquires trispecific T-cell engager from Enmabio for up to $750 million, targeting multiple myeloma.Zhitong Finance · 15 Sep 2026
GSK Target Raised to GBP22.00 From GBP20.00 by BerenbergDow Jones · 15 Sep 2026
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)TipRanks · 14 Sep 2026
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)TipRanks · 1 Sep 2026
TD Cowen Upgrades GlaxoSmithKline(GSK.US) to Buy Rating, Maintains Target Price $70Market news · 25 Aug 2026
HENGRUI PHARMA: Inside Information Announcement and Overseas Regulatory Announcement - Entering into Collaboration, Option and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited and GlaxoSmithKline Intellectual Property (No. 4) LimitedHKEX · 28 Jul 2026
Beijing Wantai Biological Pharmacy Enterprise: Announcement from Beijing Wantai Biological Pharmacy Enterprise regarding the termination of the cooperation agreement with GSK by its wholly-owned subsidiary.SZSI · 23 Jul 2026
6-K: Gsk Completes Acquisition of Idrx, Inc.SEC · 24 Feb 2026
6-K: Tesaro, A Gsk Subsidiary, Initiates Litigation Against Anaptysbio, Inc.SEC · 21 Nov 2026
6-K: Gsk Enters Agreement to Acquire Idrx, Inc.SEC · 13 Jan 2026